X

Trial Profile

A Multicenter, Nonrandomized, Open-Label Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of ICP-723 in Patients With Solid Tumors

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 29 Feb 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Zurletrectinib (Primary)
Indications Solid tumours
Focus Adverse reactions
Sponsors InnoCare Pharma

Most Recent Events

22 Feb 2024 The protocol has been amended to change in study age recruitment, now the adolescent, adult, child can take participate in this study with increase in patient population.
22 Feb 2024 Planned number of patients changed from 42 to 310.
22 Feb 2024 Planned End Date changed from 30 Dec 2022 to 1 Feb 2028.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com